IRADIMED CORPORATION Named to TIME's List of America's Growth Leaders for 2026
IRADIMED CORPORATION (NASDAQ: IRMD) was named to TIME's America's Growth Leaders for 2026, placing 79th among the top 501 U.S. public companies selected by TIME and Statista. The ranking evaluated companies equally across Revenue Growth, Financial strength, and Stock Performance using a composite model.
The company highlighted its 17 consecutive quarters of record revenue and cited sustained financial health and strong stock performance as drivers of the recognition. Management credited the award to operational execution and innovation in MRI-compatible medical devices and thanked employees and shareholders for their support.
IRADIMED CORPORATION (NASDAQ: IRMD) è stata inserita tra i TIME's America's Growth Leaders for 2026, classificandosi al 79° posto tra le prime 501 aziende pubbliche statunitensi scelte da TIME e Statista. La posizione è stata valutata dalla classifica che considera in modo uguale la crescita dei ricavi, la solvibilità finanziaria e le prestazioni delle azioni utilizzando un modello composito.
L'azienda ha evidenziato 17 trimestri consecutivi di ricavi record e ha citato una crescita finanziaria sostenuta e buone performance delle azioni come elementi trainanti il riconoscimento. Il management ha attribuito il premio all'esecuzione operativa e all'innovazione nei dispositivi medici compatibili MRI e ha ringraziato dipendenti e azionisti per il loro sostegno.
IRADIMED CORPORATION (NASDAQ: IRMD) fue nombrada entre los Líderes de Crecimiento de Estados Unidos de TIME para 2026, ubicándose en el 79.º lugar entre las 501 principales empresas públicas de EE. UU. seleccionadas por TIME y Statista. El ranking evaluó a las empresas de forma igual en crecimiento de ingresos, fortaleza financiera y rendimiento de las acciones utilizando un modelo compuesto.
La empresa destacó sus 17 trimestres consecutivos de ingresos récord y citó una salud financiera sostenida y un sólido rendimiento de las acciones como impulsores del reconocimiento. La dirección atribuyó el premio a la ejecución operativa y a la innovación en dispositivos médicos compatibles con MRI y agradeció a empleados y accionistas por su apoyo.
IRADIMED CORPORATION (NASDAQ: IRMD)는 TIME과 Statista가 선정한 TIME's America's Growth Leaders for 2026에 포함되어 미국의 상장 기업 501곳 중 79위를 차지했습니다. 이 순위는 매출 성장, 재무 건전성, 주가 성과를 동등하게 평가하는 합성 모델을 사용했습니다.
회사는 연속 17분기 기록적 매출을 강조했고, 지속적인 재무 건강과 강한 주가 성과를 인정의 원동력으로 밝혔습니다. 경영진은 이 상을 운영적 실행과 MRI 호환 의료기기의 혁신에 돌려 감사의 뜻을 밝히고 직원과 주주들에게 지원에 감사를 표했습니다.
IRADIMED CORPORATION (NASDAQ: IRMD) a été nommée parmi les Leading Growth des États-Unis de TIME pour 2026, se plaçant à la 79e place parmi les 501 meilleures sociétés publiques américaines sélectionnées par TIME et Statista. Le classement évaluait les entreprises de manière équitable sur la croissance des revenus, la solidité financière et la performance des actions en utilisant un modèle composite.
L'entreprise a mis en avant ses 17 trimestres consécutifs de revenus records et a évoqué une santé financière soutenue et une forte performance des actions comme moteurs de la reconnaissance. La direction a attribué le prix à l'exécution opérationnelle et à l'innovation dans les dispositifs médicaux compatibles IRM et a remercié les employés et les actionnaires pour leur soutien.
IRADIMED CORPORATION (NASDAQ: IRMD) wurde zu den TIME's America's Growth Leaders for 2026 aufgenommen und belegte 79. Platz unter den 501 führenden US-Börsenunternehmen, die von TIME und Statista ausgewählt wurden. Die Rangliste bewertete die Unternehmen gleichmäßig in den Bereichen Umsatzwachstum, finanzielle Stabilität und Aktienperformance anhand eines Kombination-Modells.
Das Unternehmen hob seine 17 aufeinanderfolgenden Quartale mit Rekordumsatz hervor und nannte anhaltende finanzielle Gesundheit und eine starke Aktienperformance als Triebfedern der Anerkennung. Das Management schrieb die Auszeichnung der operativen Umsetzung und Innovation bei MRI-kompatiblen medizinischen Geräten zu und dankte Mitarbeitern und Aktionären für ihre Unterstützung.
IRADIMED CORPORATION (NASDAQ: IRMD) تم اختيارها ضمن قادة النمو في أمريكا من TIME لعام 2026، حيث احتلت المركز 79 من بين أعلى 501 شركة عامة أمريكية مختارة من TIME و Statista. الترتيب قيَّم الشركات بالتساوي عبر نمو الإيرادات، الصلابة المالية و أداء الأسهم باستخدام نموذج مركب.
وأشارت الشركة إلى 17 فصلاً ربعياً متتالياً من إيرادات قياسية وذكرت أن الصحة المالية المستمرة وأداء الأسهم القوي هما المحركان وراء هذا الاعتراف. وأرجع المديرون الجائزة إلى التنفيذ التشغيلي والابتكار في الأجهزة الطبية المتوافقة مع MRI وشكروا الموظفين والمساهمين على دعمهم.
- Ranked 79th on TIME's America's Growth Leaders for 2026
- 17 consecutive quarters of record revenue
- None.
Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance
ORLANDO, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative magnetic resonance imaging (MRI)-compatible medical devices, today announced its selection to TIME's prestigious list of America's Growth Leaders for 2026. This marks the Company's recognition among the top U.S. companies demonstrating outstanding growth, as determined by TIME and Statista.
The ranking evaluated thousands of public companies across three key dimensions: Revenue Growth, Financial, and Stock Performance. Scores from these dimensions were weighted equally in a comprehensive model, with the highest-scoring 501 companies earning the distinction of "America's Growth Leaders of 2026.” Iradimed ranked 79th on the list.
“We are honored to be named to TIME's America's Growth Leaders for 2026,” said Roger Susi, President and Chief Executive Officer of Iradimed. “This recognition reflects our team's relentless commitment to innovation, operational excellence, and delivering long-term shareholder return. Our consistent revenue growth—highlighted by 17 consecutive quarters of record revenue—along with strong financial health and stock performance, underscores the success of our strategy in the MRI-compatible medical device market. We extend our deepest gratitude to our employees for their hard work and dedication, and to our shareholders for their continued support.”
For more information and the complete list, visit: https://time.com/7327022/americas-growth-leaders-2025/.
About the Methodology
TIME and Statista evaluated U.S.-based public companies using a rigorous, data-driven approach across three equally weighted dimensions:
- Revenue Growth: Focused on compound annual growth rate (CAGR) from 2021 to 2024, with a minimum revenue threshold.
- Financial Stability: Analyzed profitability alongside classic metrics such as the Piotroski F-Score and Altman Z-Score.
- Stock Performance: Assessed using multiple KPIs, including average annual growth rate, recent returns, comparison to the overall market, and volatility over the past five years.
Data was consolidated into a scoring model with a maximum of 100 points. The 501 companies with the highest scores were named America's Growth Leaders of 2026.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed for safe use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can cause radio-frequency interference and are dangerous to operate in the presence of the powerful magnet used in an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, allowing it to operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, increasing patient safety through uninterrupted vital signs monitoring and reducing the time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and an optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system features an easy-to-use design and enables effective communication of patient vital signs information to clinicians.
For more information, please visit www.iradimed.com.
Media Contact:
Jack Glenn
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
FAQ
What ranking did IRADIMED (IRMD) achieve on TIME's America's Growth Leaders 2026 list?
Why was IRADIMED (IRMD) selected for TIME's America's Growth Leaders 2026?
What operational milestone did IRADIMED (IRMD) highlight in the announcement on Nov 10, 2025?
When did IRADIMED announce its inclusion on TIME's America's Growth Leaders list?
How many companies were named to TIME's America's Growth Leaders for 2026?
Where can investors view the full TIME America's Growth Leaders list referenced by IRADIMED (IRMD)?
